key: cord-289650-q2io8vgi
authors: Hammond, Ffion R.; Lewis, Amy; Elks, Philip M.
title: If it’s not one thing, HIF’s another: immunoregulation by hypoxia inducible factors in disease
date: 2020-07-06
journal: FEBS J
DOI: 10.1111/febs.15476
sha: 
doc_id: 289650
cord_uid: q2io8vgi

Hypoxia Inducible Factors (HIFs) have emerged in recent years as critical regulators of immunity. Localised, low oxygen tension is a hallmark of inflamed and infected tissues. Subsequent myeloid cell HIF stabilisation plays key roles in the innate immune response, alongside emerging oxygen‐independent roles. Manipulation of regulatory proteins of the HIF transcription factor family can profoundly influence inflammatory profiles, innate immune cell function and pathogen clearance and, as such, has been proposed as a therapeutic strategy against inflammatory diseases. The direction and mode of HIF manipulation as a therapy is dictated by the inflammatory properties of the disease in question, with innate immune cell HIF reduction being, in general, advantageous during chronic inflammatory conditions, while upregulation of HIF is beneficial during infections. The therapeutic potential of targeting myeloid HIFs, both genetically and pharmacologically, has been recently illuminated in vitro and in vivo, with an emerging range of inhibitory and activating strategies becoming available. This review focuses on cutting edge findings that uncover the roles of myeloid cell HIF signalling on immunoregulation in the contexts of inflammation and infection, and explores future directions of potential therapeutic strategies.

Hypoxia Inducible Factors (HIFs) are master transcriptional regulators of the cellular response to hypoxia, that have influential roles in innate immune cell behaviour during inflammation and infections [1] . HIF activity is tightly regulated, both at the transcriptional and post-translational levels [2, 3] . The major point of control is regulation of protein degradation of the HIF-α subunits. In normal oxygen conditions (normoxia) the alpha subunits are hydroxylated by prolyl hydroxylase domain (PHD) enzymes leading to subsequent degradation by the proteasome (Figure 1 ). PHD enzymes require oxygen for their enzymatic activity, and so when oxygen levels drop, PHDs become inactive and HIF-α is stabilised, translocating to the nucleus to form its transcription factor complex that activates downstream genes. Multiple isoforms of the alpha subunit (HIF-1α, HIF-2α and HIF-3α) contribute to an extra level of regulatory complexity [4, 5] , and while HIF-1α is the most widely characterised, important roles of HIF-2α in immunity are emerging [6] .

The HIF-3α gene is the least understood of the isoforms, with alternative transcriptional start and splice sites contributing to different HIF-3α variants that can have opposing functions [7] . Partially due to this complexity, the roles of HIF-3α in immunity remain elusive.

This article is protected by copyright. All rights reserved HIF researchers were awarded the Nobel Prize in Physiology or Medicine in 2019 for their discoveries on the regulation of the cellular hypoxia response, with their medical research predominantly focusing on HIFs' potential role as a therapeutic target to combat anaemia, due to HIF's activating effect on red blood cell production [8] . Other blood cells, especially those of the myeloid lineage of innate immunity, are exquisitely sensitive to HIF modulation, due to their adaption to functioning in locations of low oxygen tension (for example wounds or infected tissues) [9] . The effects of HIF modulation on immune cells are wide-ranging and context dependent. Over the past decade HIFs have emerged as attractive targets for immunoregulation and immunotherapy due to their ability to profoundly influence immune cell behaviour and function, combined with roles in regulating inflammatory phenotypes in other cell types of the diseased tissue milieu.

Here, we explore recent developments that illuminate HIFs' roles in innate immunity and highlight HIF signalling components as therapeutic targets in multiple disease settings.

HIFs are key regulators of myeloid innate immune cell function, influencing survival, migration and polarisation [9] . During infection and inflammation, HIF-α is stabilised in immune cell populations, partially driven by the hypoxic tissue context of disease, alongside oxygen independent activation [10].

Neutrophils are the first innate immune cell responders to wounds or infections in many disease contexts and are exquisitely sensitive to low oxygen levels. HIF-1α stabilisation increases the lifespan of neutrophils and their bactericidal capabilities in multiple experimental models [11, 12] . Neutrophil degranulation is an important process in pathogen control, but can cause extensive tissue damage when uncontrolled in chronic inflammatory diseases where tissue hypoxia is often a hallmark [13] . Human neutrophils in hypoxia have augmented degranulation, while neutrophils with stabilised HIF-α, after treatment with the pan hydroxylase inhibitor, dimethyloxalylglycine (DMOG), interestingly do not have the same increased degranulation [14] . A dichotomy between physiological hypoxia and HIF stabilisation is also observed in neutrophil extracellular trap (NET) formation, a mechanism by which toxic components of the neutrophil (including histones, neutrophil elastase and granules) are ejected into the tissue microenvironment [15] .

This article is protected by copyright. All rights reserved including chronic obstructive pulmonary disease (COPD), asthma and post-COVID-19 lung inflammation [16] [17] [18] . Neutrophils produce fewer NETs in hypoxic conditions, due to NET formation requiring the oxygen-dependent respiratory burst [15] . Hypoxia is even able to ablate NET production when human blood-derived neutrophils are exposed to the most potent NET inducing chemical, phorbol myristate acetate (PMA) [15] . However, HIF stabilisation in normoxia has been shown to increase neutrophil NET formation through [23], although in other disease situations IL-6 is associated with pro-inflammatory profiles [28] . Macrophage behaviours during wound repair can be improved using HIF directed therapies. In a mouse model of chronic kidney disease the PHD inhibitor MK-8617, increased the infiltration of macrophages into damaged muscle, improving muscle repair and reducing muscle atrophy [29] . Additionally, treatment of HIF-α inhibitor YC-1, in a mouse injury model decreased numbers of pro-inflammatory macrophages in scar tissue, and reduced levels of proinflammatory cytokines in vivo [30] . These studies indicate that

This article is protected by copyright. All rights reserved macrophage HIF targeted therapies could allow a return to tissue homeostasis after injury/inflammation.

Chronic inflammation underpins diseases that are characterised by a hyperinflammatory profile with extensive immune cell-induced tissue damage. High levels of hypoxia and HIF-1α are associated with many of these conditions, including asthma, COPD, rheumatoid arthritis (RA), colitis and atherosclerosis [31] [32] [33] [34] . Furthermore, HIF signalling interplays with key inflammatory signalling pathways, including glucocorticoids, mTOR and arachidonic acid [35] [36] [37] .

Targeting excessive HIF can be beneficial in the outcome of chronic inflammatory diseases. In a mouse model of asthma, suppression of HIF-1α with YC-1 reduced expression of IL-5, IL-13, myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS), which alleviated asthma symptoms [31] . In the highly-inflammatory, granulomatous condition of sarcoidosis, down-regulation of HIF-1α through genetic or pharmacological means, reduced pro-inflammatory IL-1β, IL-17 and IL-6 and improved disease outcomes [38] . However, downregulation of HIF-1α can also be detrimental in some inflammation-related conditions. HIF-1α deficiency in B cells exacerbates collageninduced arthritis via impairment of IL-10 and B cell expansion, highlighting a need to target specific immune cell subsets [39] . Stabilising HIF-α subunits using hydroxylase inhibitors has been shown to be beneficial in some inflammatory conditions. DMOG suppresses the progression of periapical bone loss and attenuated inflammatory cell infiltration in apical periodontitis [40] . DMOG was also beneficial in a rat ischemia model, reducing infarction size and increasing IL-4 and IL-10 induced protection [41] . In a mouse model of multiple sclerosis, the dual peroxisome proliferator-activated receptor gamma (PPAR) and CB 2 agonist, VCE-004.8, was able to alleviate neuroinflammation and demyelination through inhibition of pro-inflammatory cytokines, via activation of HIF [42] .

These anti-inflammatory effects of HIF are emerging, and are likely to be a diseasedtissue specific effect. DMOG treatment of macrophages directly increases expression of pro-inflammatory factors such as iNOS and decreases anti-inflammatory factors such as Arginase [43] . This can be highly detrimental in inflammatory conditions. For example in an RA mouse model, HIF-1α stabilisation with Cobalt chloride (CoCl 2 ) in combination with

IL-17, is associated with increased disease severity [44] . Stabilising HIF-α in inflammatory diseases is therefore likely to be detrimental due to proinflammatory effects, although tissue and disease specific benefits may also occur.

Together these recent findings demonstrate the potential of HIF regulation to treat chronic inflammatory conditions through modulation of the myeloid component. However, treatments that target HIF can have pleiotropic effects, that differ in multiple cell types that are present in disease tissue contexts, and may require specific targeting. in TB host defence [46] . Furthermore, HIF-1α KO BMDMs have compromised lipid droplet formation, sites of eicosanoid synthesis that are required for host TB defence [47] .

During early infection, HIF-1α stabilisation is beneficial for innate immune control of TB.

In a zebrafish TB model, using the fish-adapted pathogen and close genetic relative of Mtb, Mycobacterium marinum (Mm), Hif-1α stabilisation increased myeloid production of Il-1, vital for decreasing bacterial burden via neutrophil nitric oxide (NO) production [48, 49] , alongside increasing proinflammatory macrophage Tnfa production [50] . The HIF-induced, host NO response, has also shown to be important in a mouse model of TB infection, with HIF-1α and iNOS in a positive feedback loop, balancing the inflammatory phenotype [51] . However, too much HIF-1α during later stage TB infection can be detrimental, as HIF-1α regulators prevent excess inflammation and host damage during

This article is protected by copyright. All rights reserved active disease. IL-17 has been shown to limit HIF-1α expression in a murine model, with anti-IL-17 leading to an increased number of HIF-1α positive macrophages and larger TB lesions [45] . Inhibition of HIF-1α in these anti-IL-17 mice improved infection outcome, reducing granuloma size and reversing excess inflammation [45] . Together these recent data show critical roles of HIF-1α in both innate immune cell TB control and in later stage granuloma pathogenesis.

Recent studies have added to the large bulk of evidence showing that HIF stabilisation is critical for the control of multiple bacterial infections [52, 53] . Helicobacter pylori infection of human gastric tissue stabilised HIF-1α but not HIF-2α, with HIF-2α expression decreasing as disease severity increased [54] . HIF-1α was shown to be crucial for bacterial killing of Helicobacter pylori as HIF-1α KO neutrophils possessed 66% more surviving bacteria and KO macrophages had 5 times more surviving bacteria compared to wildtype [54] . HIF-1α KO mice are also more susceptible to Listeria monocytogenes infection, possessing higher bacterial burdens and more severe pathological inflammation of the liver [55] . In a mouse model of uropathogenic Escherichia coli (UPEC), stabilising HIF-1α using the hydroxylase inhibitor AKB-4924, reduced bacterial burden by ~40% and attenuated the virulence of a hyper-infective UPEC strain [56] . Interestingly, activation of HIF-1α in this way reduced the inflammatory profile in the murine bladder context, another example of HIF-α stabilisation leading to reduced inflammation. The bactericidal properties of HIF-1α stabilisation have now been moved into clinical settings, with promising results from CoCl 2 containing bandages, that not only prevented bacterial survival and growth, but also promoted wound healing both in vitro and in vivo in a mouse infection model [57] . These recent studies highlight how host HIF-1α could be stabilised to improve bacterial infection outcomes, particularly relevant due to rising occurrence of multi-drug resistant bacterial strains.

Fungal infections are an emerging global concern and recent studies have demonstrated important roles for HIF in their pathogenesis. Myeloid HIF-1α KO mice were more susceptible to Candida albicans infection and have reduced NO and glycolytic activity [55] . Promoting HIF-1α stabilisation with the hydroxylase inhibitor CoCl 2 promoted fungal death in vitro (human macrophages) and in vivo (mouse) indicating a therapeutic potential for HIF-1α manipulation in candida infection [55] . Activation of HIF-1α has even

This article is protected by copyright. All rights reserved emerged as being a natural mechanism by which commensal bacteria inhibit Candida albicans colonisation in the gut [58] . Infection of myeloid specific HIF-1α KO mice with Histoplasma capsulatum had an increased anti-inflammatory macrophage signature, increased fungal burden and decreased mouse survival, indicating important roles of HIF in infection control [59] . However, alveolar macrophage (AM) specific HIF-1α KO mice have comparable survival compared to WT, suggesting a contribution from other cells of the myeloid lineage [59] . These studies indicate an opportunity to stabilise HIF-1α in hard-to-treat fungal infections. However, as some fungi are capable of producing and releasing their own proline hydroxylases, the effectiveness of PHD inhibitors as a therapy remains unclear [60] .

Some parasitic infections are able to circumvent host immunity by either failing to raise a proinflammatory response or, by mechanisms that actively reduce the host proinflammatory response. Trypanosoma brucei suppresses host HIF-1α through production of indolepyruvate, a ketoacid reported to be a cofactor of PHDs, promoting HIF-1α degradation [61] . Therefore, in trypanosome infections it may be beneficial to stabilise HIF-1α therapeutically. Conversely, Leishmania donovani infection increases levels of HIF-1α, and silencing HIF-1α in murine peritoneal macrophages reduced both parasitic load and infectivity at 24 hours post infection [62] . BMDMs from HIF-1α deficient mice were more resistant to L. donovani infection, expressed more ROS, and were parasitised less compared to wildtype [63] . However, a recent study has shown that L.

donovani infected HIF-1α deficient mice developed hypertriglyceridemia and lipid accumulation in splenic and hepatic myeloid cells, which impaired host defence [64] .

Together these studies suggest that parasites are able to manipulate HIF-1α levels in a variety of ways as part of their circumvention of the host immune response, creating an opportunity to target HIF-1α to improve infection outcome that has yet to be fully explored.

Due to the complexity of innate immune contributions to inflammatory and infectious diseases, targeting the correct HIF proteins, in the correct cells, at the correct time may be important considerations for any therapeutic strategy.

This article is protected by copyright. All rights reserved Recent in vitro and in vivo model studies described here have largely focused on hydroxylase inhibition as the potential HIF modulation therapy. The most successful hydroxylase inhibitor in human trials is Roxadustat, (otherwise known as FG-4592).

Roxadustat has undergone phase 3 clinical trials for chronic kidney disease induced anaemia, and was able to successfully increase patient haemoglobin levels over a prolonged 8-18 week period [65] . Other hydroxylase inhibitors used in clinical trials of various stages in recent years include, Molidustat [66] , Vadadustat (or AKB-6548) [67] , and Daprodustat (GSK1278863) [68] . Recently, a study has shown that HIF-α stabilisation can also be achieved by intrabody targeting of PHD2 [69] . HIF modulation via hydroxylase inhibition stabilises all HIF-α isoforms, but there are emerging methods to modulate HIF-α more directly. PT2385 is a HIF-2α specific inhibitor that has been investigated in the first in-human safety study and was shown to be well tolerated with a favourable safety profile for patients with Clear Cell Renal Cell Carcinoma (CCRCC) [70] , and may open the way for specific HIF-α isoform stabilisation in future therapies against inflammatory diseases.

It is interesting to note that current clinical trials for anaemia and CCRCC have used oral doses of HIF targeting drugs, without delivery to specific cell types [65] . While there are no immediate indications that wholebody HIF-drug delivery is detrimental in the short term, this review highlights that in complex inflammatory conditions targeting the wrong HIF-α isoform in the wrong cell type could be detrimental to disease outcome. For example, it was recently shown in a model of chronic inflammation of the cornea (Herpes Stromal Keratitis), that HIF-1α was high in the myeloid lineage, whereas HIF-2α was higher in epithelial cells, highlighting how different cell types in close proximity regulate HIF signalling differently and may need to be targeted separately in disease [71] . The potential of HIF-1α stabilisation to contribute to inflammatory and infectious comorbidities has recently been explored in zebrafish models, where it was shown that although Hif-1α stabilisation delays neutrophil inflammation resolution, a host-protective effect against mycobacterial infection remains [72] . A potentially important step in immunoregulatory therapies would be cell specific targeting of HIF drugs in a timely way. Drug delivery methods, such as pH sensitive liposomes and liquid emulsion systems, have been used for timely delivery of HIF targeting drugs to specific tissues in animal models of disease [73, 74] . Emerging technologies, such as synthetic polymersomes that are preferentially Accepted Article taken up by innate immune cells, could be employed to deliver HIF targeted drugs to myeloid cells during infection and inflammation [75] . Gene therapy methods have also been explored, with nanoparticle delivery of siRNA for HIF-1α used to genetically manipulate HIF in a murine model of hypoxic tumour growth [76] .

In conclusion, hypoxia and HIF stabilisation are hallmark characteristics of progressed tissue inflammation and infection. The effects of HIF modulation on the innate immune response are profound, with recent findings illustrating that HIF's effects can be complex and disease specific. Studies in in vitro and in vivo models indicate that HIF modulation during inflammation and infections may be promising therapeutic strategies against these hard-to-treat diseases. Subtle fine-tuning of the innate immune system via HIF manipulation to achieve a balance between protection against pathogens and hyperinflammation will be an important consideration to develop future therapies that target host immune cells during diseases of inflammation and infection. 

This article is protected by copyright. All rights reserved outcomes. Generally, HIF-1α stabilisation is beneficial in the context of bacterial infections, for example Mycobacterium tuberculosis/marinum (blue column), however the level of HIF-1α must be carefully balanced, with too little or too much resulting in excess inflammation and detrimental infection outcome. HIF-1α knockouts have decreases in IFN [77] , IL-1 [51] , and IL-6 [51] leading to excess tissue damage and lower survival [46] . Early HIF-1α stabilisation increases inflammatory factors leading to myeloid control of infection [48] [49] [50] , while excessive HIF-1α can lead to prolonged inflammation and larger TB lesions in later stage disease [51] . In the context of the fungal infection Candida albicans (yellow column), HIF-1α knockout decreases proinflammatory factors while increasing anti-inflammatory IL-10 leading to increased fungal survival [55] . HIF-1α stabilisation improves infection outcome, re-arming the host inflammatory response leading to increased fungal death [55, 58] . In the parasitic infection Leishmania donovani (purple column), reducing HIF-1α improves infection outcome, as the parasite itself upregulates host HIF-1α, and stabilised HIF-1α prevents CD8+ T cell expansion, exacerbating the infection further [62] [63] [64] 78] . Each infection context is distinct, requiring a tailored and controlled HIF-α response that is not uniform across infections.

Biophysica Acta The pro-and anti-in fl ammatory properties of the cytokine interleukin-6

Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease

Pharmacological HIF-inhibition attenuates postoperative adhesion formation

Hypoxia-inducible factor-1 α inhibition modulates airway hyperresponsiveness and nitric oxide levels in a BALB / c mouse model of asthma

Myeloid Cell Hypoxia-Inducible Factors Promote Resolution of Inflammation in Experimental Colitis

Correlation of serum levels of HIF-1 α and IL-19 with the disease progression of COPD : a retrospective study

Mechanical Activation of Hypoxia-Inducible Factor 1 α Drives Endothelial Dysfunction at Atheroprone Sites. Arter

Bidirectional crosstalk between Hypoxia-Inducible Factor and glucocorticoid signalling in zebrafish larvae

Glucocorticoids promote Von Hippel Lindau degradation and Hif-1 α stabilization

Accepted Article This article is protected by copyright. All rights reserved

Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation

HIF-1 a regulates IL-1 b and IL-17 in sarcoidosis

Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease

Activation of hypoxia-inducible factor 1 attenuates periapical inflammation and bone loss

Hypoxia Inducible Factor 1 a Plays a Key Role in Remote Ischemic Preconditioning Against Stroke by Modulating In fl ammatory

Hypoxia mimetic activity of VCE-004 . 8 , a cannabidiol quinone derivative : implications for multiple sclerosis therapy

PHD2 Is a Regulator for Glycolytic Reprogramming in Macrophages

Interleukin 17 under hypoxia mimetic condition augments osteoclast mediated bone erosion and expression of HIF-1 α and MMP-9

Interleukin-17 limits hypoxia-inducible factor 1 α and development of hypoxic granulomas during tuberculosis

Myeloid HIF-1 a regulates pulmonary inflammation during experimental Mycobacterium tuberculosis infection

Lipid droplet formation in Mycobacterium tuberculosis infected macrophages requires IFN-γ / HIF-1 α signaling and supports host defense

PLOS Pathogens: Hypoxia Inducible Factor Signaling Modulates Susceptibility to Mycobacterial Infection via a Nitric Oxide Dependent Mechanism

Hif-1 α − Induced Expression of Il-1 β Protects against Mycobacterial Infection in Zebrafish

Hypoxia Induces Macrophage tnfa Expression via Cyclooxygenase and Prostaglandin E2 in vivo

Nitric Oxide Modulates Macrophage Responses to Mycobacterium tuberculosis Infection through Activation of HIF-1 α and Repression of NF-κ B

The Impact of Hypoxia on the Host-Pathogen Interaction between Neutrophils and Staphylococcus aureus

Interdependence of hypoxic and innate immune responses

Myeloid HIF-1 Is Protective in Helicobacter pylori − Mediated Gastritis

HIF1 α -dependent glycolysis promotes macrophage functional activities in protecting against bacterial and fungal infection

Role of Hypoxia Inducible Factor-1 α ( HIF-1 α ) in Innate Defense against Uropathogenic Escherichia coli Infection

Cobalt-mediated multi-functional dressings promote bacteria-infected wound healing

Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization

Inverse Correlation between IL-10 and HIF-1 α in Macrophages Infected with Histoplasma capsulatum

Biochemical and genetic characterization of fungal proline hydroxylase in echinocandin biosynthesis

Trypanosoma brucei metabolite indolepyruvate decreases HIF-1 α and glycolysis in macrophages as a mechanism of innate immune evasion

Leishmania donovani Activates Hypoxia Inducible Factor-1 α and miR-210 for Survival in Macrophages by Downregulation of NF-κ B Mediated Proinflammatory Immune Response

HIF-1αlpha hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis

The Absence of HIF-1 a Increases Susceptibility to Leishmania donovani Infection via Activation of BNIP3 / mTOR / SREBP-1c Axis

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N. Accepted Article This article is protected by copyright. All rights reserved Engl

First-in-man -proof of concept study with molidustat : a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

Original Investigation A Novel Hypoxia-Inducible Factor 2 Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Intrabody against prolyl hydroxylase 2 promotes angiogenesis by stabilizing hypoxiainducible factor-1 α

Phase I Dose-Escalation Trial of PT2385 , a First-in-Class Hypoxia-Inducible Factor-2 a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Development of Inflammatory Hypoxia and Prevalence of Glycolytic Metabolism in Progressing Herpes Stromal Keratitis Lesions

Hif-1alpha stabilisation is protective against infection in zebrafish comorbid models

Programmed delivery of cyclopeptide RA-V and antisense oligonucleotides for combination therapy on hypoxic tumors and for therapeutic

Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced ef fi cacy with reduced systemic exposure in a murine model of colitis

Therapeutic Delivery of siRNA Silencing HIF -1 Alpha with Micellar Nanoparticles Inhibits Hypoxic Tumor Growth

HIF-1α Is an Essential Mediator of IFN-γ-Dependent Immunity to Mycobacterium tuberculosis